Tan Tock Seng Hospital | Clinical Research and Innovation Office
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
Prior allogenic stem cell or solid organ transplantation
Untreated symptomatic central nervous system (CNS) metastases
Clinically significant ascites as defined by:
i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment
Other protocol-defined inclusion/exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
162 participants in 2 patient groups
Loading...
Central trial contact
BMS Study Connect Contact Center www.BMSStudyConnect.com; First line of the email MUST contain NCT # and Site #.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal